Darmiyan GTM brain

category

market profile

• text: BrainSee combines MRI and cognitive assessments to aid prognosis, rather than serving as a general screening test for asymptomatic people.
• text: The FDA's De Novo authorization specifies patients aged 55 to 95 diagnosed with amnestic MCI and a five-year clinical Alzheimer's dementia horizon.
• text: A research center reports third-party validation on blinded MRI data; assess the study and intended-use limitations before extrapolating performance.

personas

• title: Neurologist or memory clinic physician
  pains:

  • Patients with amnestic MCI need an understandable prognosis despite substantial uncertainty.
  • Clinicians need evidence alongside clinical assessment when discussing likely progression.
• title: Health system neurology service leader
  pains:

  • Introducing a new diagnostic workflow requires clinical validation, MRI access and integration into existing referrals.
  • Coverage and patient out-of-pocket costs need verification.
• title: Alzheimer's clinical research lead
  pains:

  • Needs quantitative ways to evaluate brain changes in research populations.
  • Must establish whether the tool is appropriate for a specific research protocol separately from its clinical indication.

icp

• text: US memory clinics, neurology practices and health systems seeing patients aged 55 to 95 with diagnosed amnestic MCI and access to qualifying brain MRI and cognitive assessments.
• text: Brain-health research organizations and pharmaceutical teams investigating neurodegeneration are adjacent prospects; research applications require separate validation.

message pillars

• text: Combine existing MRI with cognitive assessments to inform prognosis.
• text: Focus on earlier understanding of neurodegeneration.
• text: Emphasize non-invasive and accessible brain tests as the company's design goals.

objections

• objection: Is this a general Alzheimer's screening test?
  response: No: review the FDA indication and limitations; it supports prognosis for a defined aMCI population, not universal screening.
• objection: Will it fit our workflow and payer requirements?
  response: Confirm qualifying MRI inputs, integration, coverage and patient costs with Darmiyan and relevant payers before adoption.
• objection: How reliable is the prognostic score?
  response: Review the published independent validation and FDA evidence for the intended population and communicate uncertainty.

competitors

• name: Cortechs.ai
  why: NeuroQuant offers quantitative brain MRI analysis, an overlapping clinical imaging workflow with different indications.
• name: icometrix
  why: icobrain provides brain MRI quantification for neurological conditions; its intended uses differ from BrainSee's prognosis.
• name: DeepHealth
  why: Quantib brain imaging software supports quantitative brain MRI analysis and competes for related imaging workflows.

influencers

• name: Padideh Kamali-Zare
  url: https://darmiyan.com/news/
  why: CEO and public spokesperson on brain health technology.

keywords

• amnestic MCI prognosis
• Alzheimer progression MRI
• brain MRI AI assessment
• mild cognitive impairment risk
• Alzheimer dementia prediction
• memory clinic MRI software

voice

• Scientific
• Clinical
• Mission-driven

signals

• text: A memory clinic wants to improve prognostic discussions with eligible aMCI patients.
• text: A health system is investing in cognitive assessment pathways and already has MRI access.

pricing

motion

channels

• Clinical evidence
• Press
• Healthcare partnerships

confidence

Founders

• name: Padideh Kamali-Zare
  title: Founder
  role: Founder
  bio: I'm Padideh - brain enthusiast, data driven, and one of the brains behind Darmiyan. After my Ph.D. in Biological Physics from KTH (Sweden) and postdoc in computational neuroscience at NYU (New York), I dove headfirst into the startup world to tackle a cause close to my heart: Alzheimer's. I've been on a mission to outsmart this disease since my grandmother's diagnosis. BrainSee is our first product that catches Alzheimer's early and give people a fighting chance.
• name: Kaveh Vejdani
  title: Founder/Chief Medical and Technology Officer
  role: Founder